Kerry Group plc stock (IE0004906560): EFSA boost puts coffee enzyme in focus

Kerry Group plc is back in the spotlight after the European Food Safety Authority (EFSA) issued a positive scientific opinion on Acrylerase, a novel amidase food enzyme designed to reduce acrylamide levels in coffee extracts used for instant coffee and coffee substitutes, according to a summary of the ruling published on April 24, 2025 by EFSA and reported by trade press on the same day EFSA as of 04/24/2025.

Market observers noted that the favorable EFSA view could strengthen Kerry Group plc’s position in process technology for coffee and hot drinks, an area where food and beverage manufacturers are looking for ways to cut acrylamide levels while preserving flavor profiles, as highlighted in sector coverage on April 25, 2025 Ad-hoc-news.de as of 04/25/2025.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

Kerry Group plc: core business model

Kerry Group plc describes itself as a global specialist in taste and nutrition solutions, supplying food, beverage and pharmaceutical manufacturers with functional ingredients, flavors, and integrated systems that help shape the final taste, texture and nutritional profile of branded and private-label products, as outlined in its corporate materials updated on February 15, 2025 Kerry Group plc as of 02/15/2025.

The group’s strategy centers on partnering closely with large consumer packaged goods companies, quick-service restaurant chains and regional food brands to co-develop new recipes and reformulate existing products, a collaboration model that Kerry says is supported by more than 150 manufacturing sites and innovation centers around the world, according to its 2024 annual report published on February 22, 2025 Kerry Group plc as of 02/22/2025.

Over the last decade the company has shifted its portfolio significantly away from commoditized dairy processing toward higher-margin taste and nutrition technologies, including enzymes, flavor modulation, plant-based protein solutions and functional ingredients aimed at health-conscious consumers, according to commentary in the 2024 annual results presentation released on February 22, 2025 Kerry Group plc as of 02/22/2025.

The EFSA ruling on Acrylerase fits into this strategic positioning, because it showcases Kerry Group plc’s ability to combine regulatory expertise with process technology and enzyme engineering, offering customers a route to address contaminants of concern such as acrylamide while maintaining sensory qualities that consumers expect from instant coffee and related products, as highlighted in coverage by a European food-industry publication on April 25, 2025 Just Food as of 04/25/2025.

Main revenue and product drivers for Kerry Group plc

Kerry Group plc generated the bulk of its 2024 revenue from its Taste & Nutrition division, which contributes solutions for beverages, snacks, bakery, dairy and meat applications, while a smaller portion comes from its consumer foods activities, according to the firm’s full-year 2024 results released on February 22, 2025 Kerry Group plc as of 02/22/2025.

Within Taste & Nutrition, management pointed to beverages, savory snacks and foodservice channels as key growth areas during 2024, supported by demand for cleaner labels, sugar reduction and improved texture, trends that the company described in an investor presentation dated February 22, 2025 Kerry Group plc as of 02/22/2025.

Enzymes such as Acrylerase are part of the broader functional ingredients toolkit that Kerry offers; while the company does not break out stand-alone enzyme revenue in its public reporting, it notes that technologies for processing efficiency, shelf-life extension and contaminant reduction are increasingly important differentiators when competing for large formulation projects, according to the 2024 annual report published on February 22, 2025 Kerry Group plc as of 02/22/2025.

On the geographic side, Kerry Group plc reports that North America and Europe remain its largest revenue contributors, while emerging markets in Asia-Pacific, Latin America, the Middle East and Africa are targeted for faster growth due to rising incomes and demand for convenient packaged foods, according to the geographical breakdown in the 2024 annual results statement released on February 22, 2025 Kerry Group plc as of 02/22/2025.

For US investors, Kerry Group plc’s role as a formulation partner to major US-based multinationals and restaurant chains means its revenue is linked not only to European consumer trends but also to the health of the US packaged food and foodservice sector, making developments such as the Acrylerase decision relevant beyond the European regulatory environment, as underlined in analysis by a US-focused food-industry news service on April 26, 2025 Food Business News as of 04/26/2025.

Why Kerry Group plc matters for US investors

Although Kerry Group plc is headquartered in Ireland and listed on Euronext Dublin and the London Stock Exchange, it generates a substantial portion of its revenue from North American customers, including US food manufacturers and quick-service restaurant chains, according to regional disclosures in the 2024 annual report published on February 22, 2025 Kerry Group plc as of 02/22/2025.

This exposure means that trends such as US consumer interest in cleaner labels, sugar and sodium reduction, and functional beverages directly influence Kerry’s project pipeline, while regulatory developments in Europe, such as EFSA opinions, can indirectly shape standards that multinational US-headquartered brands adopt worldwide, as noted by an international consumer-goods research house in commentary dated March 5, 2025 S&P Global Market Intelligence as of 03/05/2025.

For US-based investors who follow global ingredients suppliers as part of the broader consumer staples and food-technology universe, Kerry Group plc sits alongside peer companies that are also listed in Europe but have significant North American operations, offering a different regional risk mix compared with purely domestic US stocks, as illustrated in sector comparisons published on April 18, 2025 Bloomberg as of 04/18/2025.

Conclusion

The positive EFSA scientific opinion on Acrylerase highlights Kerry Group plc’s focus on specialized enzyme and process technologies that help food and beverage manufacturers address acrylamide and other process contaminants while preserving product quality, which is a key concern in categories such as instant coffee and coffee substitutes, according to regulatory and industry documents dated April 24–25, 2025 EFSA as of 04/24/2025.

At the same time, Kerry Group plc remains closely tied to broader trends in the global packaged food and beverage industry, with its performance influenced by customer innovation cycles, input-cost dynamics and consumer preferences in key markets such as the United States and Europe, as described in its full-year 2024 results published on February 22, 2025 Kerry Group plc as of 02/22/2025.

For investors watching the international food-ingredients space from the US, Kerry Group plc’s developments, including regulatory milestones like the Acrylerase decision, form part of a wider picture that also includes competitive positioning, regional growth opportunities and the company’s ongoing strategic shift toward higher-value taste and nutrition solutions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.